Esteemed life sciences executive with extensive veterinary biologics and animal health expertise
Invetx, a company focusing on protein-based therapeutics for animal health, has recently appointed Marcus Remmers, PhD, to its board of directors.
“We are pleased to welcome Dr Remmers, an accomplished life sciences executive with significant veterinary biologics and animal health expertise, to our board of directors,” expressed Juergen Horn, PhD, chief executive officer, Invetx, in a company release.1 “He will be a valuable addition as we advance our pipeline of novel antibody therapeutics targeting chronic and serious diseases in dogs and cats.”
Currently a partner at Novo Holdings and a member of the World Economic Forum’s Expert Network, Remmers most recent position was as chief technology officer at DSM, a global health, nutrition, and bioscience company. Before that, he was vice president, global head of biologics R&D and vice president, global head of pharma R&D at Merial, a veterinary medicine company acquired by Boehringer Ingelheim Animal Health in 2017. Earlier in his career, he worked as a country president for Intervet (later Schering-Plough Animal Health). He achieved degrees in chemistry from the University of Munster and University of Freiburg, and a doctorate in chemistry from the Max Planck Institute for Polymer Research.1
“I am excited to join the board of directors of Invetx and be part of the company’s remarkable journey,” stated Remmers.1 “I believe that Invetx’s powerful platform and impressive product pipeline will unlock great opportunities and deliver innovative solutions that will make a difference in the Animal Health market.”
Invetx appoints Dr Marcus Remmers, Novo Holdings partner and animal health industry leader, to board of directors. News release. Invetx. June 26, 2023. Accessed June 29, 2023. https://www.businesswire.com/news/home/20230626564216/en